- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Longeveron Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR's BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome (HLHS), a Rare Pediatric Congenital Heart Defect | 1 | GlobeNewswire (USA) | ||
| 01.10. | Longeveron Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 01.10. | Longeveron beruft Teamarzt der St. Louis Cardinals in den Verwaltungsrat | 3 | Investing.com Deutsch | ||
| 01.10. | George Paletta, Jr., MD, MBA, Internationally Acclaimed Entrepreneur, Investor and Surgeon, Elected to Longeveron Board of Directors | 1 | GlobeNewswire (USA) | ||
| 22.09. | Longeveron to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa | 1 | GlobeNewswire (USA) | ||
| LONGEVERON Aktie jetzt für 0€ handeln | |||||
| 19.09. | Longeveron Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 03.09. | Longeveron Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 03.09. | Longeveron appoints interim CEO | 2 | Seeking Alpha | ||
| 03.09. | Longeveron names Than Powell as interim CEO in leadership shuffle | 2 | Investing.com | ||
| 03.09. | Longeveron Announces Key Leadership Updates | 114 | GlobeNewswire (Europe) | Than Powell, Chief Business Officer and head of business development, appointed Interim CEODr. Joshua Hare, co-founder and chief science officer, appointed Executive Chairman of the Board of DirectorsWa'el... ► Artikel lesen | |
| 18.08. | Roth slashes price target on Longeveron | 4 | Cantech Letter | ||
| 14.08. | Longeveron reports Q2 results | 3 | Seeking Alpha | ||
| 13.08. | Longeveron Inc. Q2 Loss Declines | 1 | RTTNews | ||
| 13.08. | Longeveron Announces Second Quarter 2025 Financial Results and Provides Business Update | 288 | GlobeNewswire (Europe) | Full enrollment achieved for pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indicationELPIS... ► Artikel lesen | |
| 13.08. | Longeveron Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.08. | Preview: Longeveron's Earnings | 1 | Benzinga.com | ||
| 11.08. | Longeveron closes $5 million public offering of common stock | 2 | Investing.com | ||
| 11.08. | Longeveron Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 11.08. | Longeveron Announces Closing Of Up To $17.5 Million Public Offering | 2 | GlobeNewswire (USA) | ||
| 08.08. | Longeveron Announces Up To $17.5 Million Public Offering | 8 | GlobeNewswire (USA) |
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CUREVAC | 4,600 | -0,48 % | Turbulenzen im Biotechsektor - BioNTech, CureVac, Moderna, Vidac Pharma | Nach der stetigen Eskalation im Handelskrieg der beiden führenden Wirtschaftsnationen der Welt, USA und China, meldete der US-Finanzminister Scott Bessent, dass er zuversichtlich bezüglich des Treffens... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 56,00 | +0,90 % | CRISPR Therapeutics AG: CRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe | ZUG, Switzerland and BOSTON and SAN DIEGO and SHANGHAI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based... ► Artikel lesen | |
| OCUGEN | 1,370 | +1,60 % | Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea | Upfront fees and near-term development milestone payments totaling up to $7.5 millionPotential sales milestones of $180 million or more in first 10 years of commercializationRoyalties equaling 25%... ► Artikel lesen | |
| EDITAS MEDICINE | 2,717 | +1,19 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| CYTODYN | 0,210 | +5,00 % | CytoDyn Inc.: September 2025 Letter to Shareholders | VANCOUVER, Washington, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Dear Shareholders, As this pivotal year continues to take shape for CytoDyn Inc. ("CytoDyn" or the "Company"), I am pleased to share the... ► Artikel lesen | |
| SOL GLOBAL INVESTMENTS | 0,034 | +15,31 % | SOL Global Investments Corp.: SOL Global Announces Change of Auditor | Toronto, Ontario--(Newsfile Corp. - October 15, 2025) - SOL Global Investments Corp. (CSE: SOL) (OTCID: SOLCF) (FSE: 9SB) ("SOL Global" or the "Company") today announce that it has changed its auditor... ► Artikel lesen | |
| TRINITY BIOTECH | 1,010 | 0,00 % | Trinity Biotech plc: Trinity Biotech Welcomes Perceptive Advisor's Indication of Potential Debt-to-Equity Conversion - Strengthening Balance Sheet and Supporting Growth | ||
| FATE THERAPEUTICS | 1,183 | -0,13 % | FATE THERAPEUTICS INC - 8-K, Current Report | ||
| ANAVEX LIFE SCIENCES | 7,076 | +2,61 % | Anavex Life Sciences Corp.: Anavex Life Sciences Announces Continued Long-Term Benefit from Oral Blarcamesine Compared to Decline Observed in the Alzheimer's Disease Neuroimaging Initiative (ADNI) Control Group | ADAS-Cog13 difference -12.78 (P 77.4 Weeks (17.8 Months) 'time saved' with oral blarcamesine compared to ADNI Restoring impaired Autophagy - preceding amyloid-beta and tau NEW YORK, Oct. 29, 2025... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 10,030 | +4,26 % | Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis Program | ARCT-032 generally safe and well tolerated
Meaningful trends of clinical activity observed via high resolution CT scans
After only 28 days of treatment with ARCT-032 (10 mg), 4 out of 6 Class... ► Artikel lesen | |
| CERUS | 1,309 | +2,27 % | Cerus Corporation: The German National Blood Advisory Committee Issues Formal Recommendation for Improving the Safety of Platelet Transfusions | Cerus Corporation (Nasdaq: CERS) announced today the publication of a new recommendation from the German National Blood Advisory Committee (Arbeitskreis Blut or AK Blut), which recommends proactive... ► Artikel lesen | |
| OVID THERAPEUTICS | 1,270 | +1,60 % | Ovid Therapeutics Inc.: Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds | NEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant... ► Artikel lesen | |
| WINDTREE THERAPEUTICS | 0,108 | -1,82 % | Windtree Therapeutics: Windtree Announces Istaroxime Phase 2 Interim Analysis in SCAI Stage C Cardiogenic Shock Patients | Istaroxime was added to currently available inotropes and vasopressors in the study - no new safety signals were identified and physiological improvements were consistent with istaroxime responses... ► Artikel lesen | |
| APTEVO THERAPEUTICS | 1,260 | 0,00 % | Aptevo Therapeutics Inc. - 8-K, Current Report | ||
| HARVARD BIOSCIENCE | 0,446 | -1,33 % | Harvard Bioscience, Inc.: Harvard Bioscience Expands Distribution Agreement with Fisher Scientific to Include United States | HOLLISTON, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the "Company" or "Harvard Bioscience"), a leading provider of innovative laboratory equipment, is pleased... ► Artikel lesen |
Das Unternehmen LONGEVERON INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +0,35 % bei einem Aktienkurs von 0,831 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LONGEVERON INC finden Sie auf Wallstreet Online.